9MW2821
Sponsors
Mabwell (Shanghai) Bioscience Co., Ltd., Fudan University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Peking University Third Hospital
Conditions
Advanced Breast CancerAdvanced Malignant Solid TumorsAdvanced Urothelial CarcinomaBladder CancerBreast CancerBreast NeoplasmBreast TumorsCervical Cancer
Phase 1
A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors
NCT05216965
Start: 2022-06-11End: 2025-12-31Target: 208Updated: 2022-06-15
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
RecruitingNCT05773937
Start: 2022-06-21End: 2024-12-31Target: 40Updated: 2024-09-19
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
RecruitingNCT06079112
Start: 2023-09-27End: 2027-12-31Target: 100Updated: 2024-09-19
Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)
RecruitingNCT06551233
Start: 2024-04-22End: 2025-12-31Target: 30Updated: 2024-08-13
A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors
Not yet recruitingNCT06947226
Start: 2025-04-30End: 2027-04-30Target: 188Updated: 2025-04-27
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
RecruitingNCT05582499
Start: 2022-11-01End: 2029-09-01Target: 716Updated: 2026-05-28
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
RecruitingNCT06492005
Start: 2024-07-26End: 2027-07-31Target: 160Updated: 2025-01-10
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
RecruitingNCT06649331
Start: 2024-10-21End: 2027-09-01Target: 160Updated: 2026-04-08
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
RecruitingNCT06823427
Start: 2025-01-17End: 2027-06-30Target: 60Updated: 2025-03-21
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
RecruitingNCT07314723
Start: 2025-08-01End: 2028-12-31Target: 90Updated: 2026-01-02
NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC
Not yet recruitingNCT07412171
Start: 2026-02-01End: 2028-12-01Target: 40Updated: 2026-02-17
Phase 3
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
RecruitingNCT06196736
Start: 2023-12-29End: 2027-07-31Target: 432Updated: 2025-04-13
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
RecruitingNCT06592326
Start: 2024-08-22End: 2028-12-31Target: 460Updated: 2024-09-19
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
RecruitingNCT06692166
Start: 2024-09-10End: 2029-12-31Target: 420Updated: 2024-11-22
A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer
Not yet recruitingNCT07556848
Start: 2026-05-01End: 2028-09-01Target: 356Updated: 2026-04-30